H1N1 virus market to be worth $273 million by 2018

22 October 2013

The H1N1 vaccines market has been forecast to decline in value over the next five years, reaching a value of $273 million by 2018, reports Companiesandmarkets.com, predominantly as a result of the waning occurrences of the Influenza Type A H1N1 virus in the post-pandemic phase.

Worldwide influenza vaccine sales grew in 2009 with the introduction of vaccines to tackle the Influenza A (H1N1) pandemic virus. However, the momentum provided by Swine Flu ran out of steam by August 2010, with the World Health Organization (WHO) officially declaring the disease to have entered the post-pandemic stage.

Further outbreaks

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >